IOM Planning Committees are solely responsible for planning the workshop, identifying topic areas, and selecting speakers. The responsibility for the published workshop summary rests with the workshop participants. The workshop agenda and presentations are solely responsible for organizing the workshop, identifying topic areas, and selecting speakers. The responsibility for the published workshop summary rests with the workshop participants.
Women in Clinical Trials: FDA Policies

**Women as Subjects in Clinical Trials**

Training of sex differences in physiology and disease.

The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments. The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments. The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments. The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments. The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments.

**Women in Clinical Trials:**

Women should be enrolled in clinical trials at all stages, and differences in their responses to treatment should be considered.

**Conclusions**

The importance of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments. The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments. The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments. The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments. The finding of sex differences in physiology and disease is essential to the development and acceptance of new medical treatments.

Sex differences are significant in normal brain structure and function.
and may partly explain variance in response than common subjective
response. Differences in drug development may be engaged in predicting treatment responses
Newly developed parameters may be engaged in predicting treatment responses above the impact of sex differences in response to treatment. These parameters are important but the
impact is known.
In conclusion, Znarte noted that sex differences matter. But the
impact above the impact is known.

In his closing statement, Znarte noted that the
impact is unknown. The impact is unknown. The
impact is unknown.

In conclusion, Znarte noted that sex differences matter. But the
impact is unknown.

In conclusion, Znarte noted that sex differences matter. But the
impact is unknown. The impact is unknown. The
impact is unknown.

In conclusion, Znarte noted that sex differences matter. But the
impact is unknown.

In conclusion, Znarte noted that sex differences matter. But the
impact is unknown.